Participation in cardiovascular screening consultations, the who, when and why - A cohort study on patients with rheumatoid arthritis

Table 1 Demographic and disease characteristics of the patients who were invited to a CV screening consultation

Variables	n	Accepted invitation to screening n = 1,058	Declined invitation to screening n = 91	p-value
Age, years	1,149	60.5 (9.30)	59.4 (14.35)	0.291
Gender, men	344	308 (29%)	36 (40%)	0.037
Disease duration, years	1,128	9.37 (9.91)	10.4 (9.24)	0.350
Positive RF	296	178 (64%)	7 (41%)	0.061
Positive Anti-CCP	469	279 (64%)	15 (46%)	0.034
DAS28-CRP	942	2.63 (1.20)	3.03 (1.55)	0.017
Medical treatment	1,108
No DMARD or CS		1 (1%)	-	-
cDMARD ± CS		781 (76%)	67 (80%)	-
bDMARD ± CS		166 (16%)	9 (10%)	-
Only CS		76 (7%)	8 (10%)	0.392
Known CVD	1,054	462 (44%)	-	-
Known DM,	1,047	77 (7%)	-	-

Data presented as mean (standard deviation) or n (%).Wilcoxon’s rank-sum test was employed for continuous variables; chi-squared test for categorical variables. P-values < 0.05 considered statistically significant are presented in bold. n = number of patients with available data for each variable is provided
RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptide, DAS28-CRP disease activity score in 28 joints–CRP and patient global assessment score (0–10), DMARD disease-modifying antirheumatic drug, cDMARD conventional disease-modifying antirheumatic drugs (with or without corticosteroids), bDMARD biological disease-modifying antirheumatic drugs (with or without corticosteroids), CS corticosteroids, CVD cardiovascular diseases, DM Diabetes Mellitus

ISSN: 2520-1026